• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A. 2017 Dec 18. pii: 201715471. doi: 10.1073/pnas.1715471115. [Epub ahead of print]
[h=1]Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody.[/h] Raymond DD[SUP]1[/SUP], Bajic G[SUP]1[/SUP], Ferdman J[SUP]2[/SUP], Suphaphiphat P[SUP]2[/SUP], Settembre EC[SUP]2[/SUP], Moody MA[SUP]3,[/SUP][SUP]4[/SUP], Schmidt AG[SUP]1[/SUP], Harrison SC[SUP]5,[/SUP][SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hemagglutinin (HA). The receptor-binding site (RBS) on the HA "head" and a region near the fusion peptide on the HA "stem" are two such sites. We describe here a human antibody clonal lineage, designated CL6649, members of which bind a third conserved site ("lateral patch") on the side of the H1-subtype, HA head. A crystal structure of HA with bound Fab6649 shows the conserved antibody footprint. The site was invariant in isolates from 1977 (seasonal) to 2012 (pdm2009); antibodies in CL6649 recognize HAs from the entire period. In 2013, human H1 viruses acquired mutations in this epitope that were retained in subsequent seasons, prompting modification of the H1 vaccine component in 2017. The mutations inhibit Fab6649 binding. We infer from the rapid spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conserved lateral patch had become immunodominant for individuals with B-cell memory imprinted by earlier H1 exposure. We suggest that introduction of the pdm2009 H1 virus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage in the immune systems of infected hosts to recall of memory B cells that recognized the lateral patch, the principal exposed epitope that did not change when pdm2009 displaced previous seasonal H1 viruses.


[h=4]KEYWORDS:[/h] B-cell memory; affinity maturation; hemagglutinin; influenza vaccine

PMID: 29255041 DOI: 10.1073/pnas.1715471115
 
Back
Top Bottom